What Is Staphylococcus Hominis and Is It Dangerous?

Staphylococcus hominis is a bacterium that lives naturally on human skin, and for the vast majority of people it is completely harmless. It ranks as the second most commonly isolated coagulase-negative staphylococcal species from healthy skin and actually helps defend against more dangerous microbes. The trouble starts when it enters the bloodstream or colonizes a medical device in someone whose immune system is compromised. In those settings, S. hominis can cause serious infections that are increasingly difficult to treat because of rising antibiotic resistance.

A Normal Resident of Your Skin

S. hominis belongs to a large group of bacteria collectively called coagulase-negative staphylococci, or CoNS. The “coagulase-negative” label simply means these species lack a particular enzyme that their more famous relative, Staphylococcus aureus, uses to clot blood plasma. Dozens of CoNS species live on human skin without causing problems, and S. hominis is one of the most abundant among them. Research confirms it is the second most frequently isolated CoNS from healthy skin, trailing only Staphylococcus epidermidis.¹

You will find S. hominis especially in moist areas: the armpits, groin, and the spaces between fingers. It thrives in the specific pH and moisture conditions of those sites and has been living alongside humans long enough to be considered part of the normal skin microbiome. Under ordinary circumstances, your immune system and the physical barrier of intact skin keep S. hominis in its place, and it returns the favor by occupying ecological niches that might otherwise be claimed by more harmful bacteria.

How It Protects You From Worse Bugs

One of the more interesting things about S. hominis is that it actively fights off pathogens. Certain strains produce antimicrobial peptides that kill or inhibit dangerous species, including Staphylococcus aureus. A peptide called hominicin, isolated from S. hominis, shows potent activity against standard S. aureus strains, methicillin-resistant S. aureus (MRSA), and even vancomycin-intermediate S. aureus.² Another compound, a lantibiotic called homicorcin, has been identified from a different S. hominis strain and also demonstrates antibacterial effects against S. aureus.³

The broader picture, supported by emerging evidence, is that S. hominis may play an important role in excluding S. aureus from colonizing or infecting the skin.¹ This is part of a concept sometimes called “colonization resistance,” where the harmless bacteria already living on your skin make it harder for dangerous newcomers to gain a foothold. So paradoxically, the same organism that occasionally causes hospital infections in vulnerable patients is, on healthy skin, part of your first line of defense.

The Body Odor Connection

If you have ever wondered why armpits smell, S. hominis is part of the answer. Your sweat glands release odorless precursor molecules that skin bacteria then break down into volatile compounds you can actually smell. One of the key malodor molecules is called 3-methyl-3-sulfanylhexan-1-ol, or 3M3SH, and S. hominis is a major contributor to its production.

Research has identified the biochemical pathway involved. First, an enzyme in S. hominis acts as a dipeptidase, cleaving a precursor compound called Cys-Gly-3M3SH. A subsequent step then releases the sulfur-containing thiol that produces the characteristic smell.⁴ A 2024 study pinpointed the specific S. hominis enzyme responsible, called ShPepV, and confirmed it has dipeptidase activity on the odor precursor.⁵ This work matters beyond curiosity: understanding which enzymes drive body odor could eventually lead to more targeted deodorant formulations that inhibit the specific bacterial enzymes rather than wiping out entire microbial communities.

Two Subspecies, Very Different Reputations

Not all S. hominis are created equal. The species is divided into two recognized subspecies: S. hominis subsp. hominis and S. hominis subsp. novobiosepticus. The first is the garden-variety skin commensal most people carry. The second, identified more recently, is a genuinely concerning hospital pathogen.

S. hominis subsp. novobiosepticus differs from the standard subspecies in a few straightforward ways: it is resistant to the antibiotic novobiocin and cannot ferment the sugar trehalose. At the genetic level, the two subspecies show small but consistent differences in their 16S rRNA and DNA topoisomerase gene sequences.⁶ Labs can also distinguish them using protein profiling techniques, which detect unique protein peaks in each subspecies.⁷

Why does the distinction matter? S. hominis subsp. novobiosepticus tends to carry far more antibiotic resistance genes and has been implicated in serious hospital-acquired infections. In one investigation of a neonatal intensive care unit, 32 isolates of this subspecies were recovered from 21 patients between 2002 and 2003, with 13 neonates developing late-onset sepsis caused by a single circulating strain.⁸ It has also been identified as a cause of sepsis in cancer patients.⁹ So when clinicians worry about S. hominis as a pathogen, they are often thinking specifically about this subspecies.

When S. Hominis Becomes Dangerous

For a healthy person with intact skin and a functioning immune system, S. hominis poses essentially no risk. The danger arises in specific clinical scenarios, almost always involving one or more of these factors:

Indwelling devices: Central venous catheters, hemodialysis catheters, peritoneal dialysis catheters, prosthetic joints, and heart valves give S. hominis a direct route past the skin barrier into the bloodstream or sterile body sites.
Immune suppression: Cancer patients undergoing chemotherapy, organ transplant recipients on immunosuppressive drugs, and people with advanced HIV infection are all at heightened risk.
Premature neonates: Babies born very early have underdeveloped immune systems and often need indwelling catheters, putting them in double jeopardy.

Catheter-related bloodstream infections are the most common clinical presentation. S. hominis has been documented as a cause of polyclonal bacteremia originating from infected central venous catheters in cancer patients, sometimes alongside S. epidermidis.¹⁰ It has also been identified among organisms causing bloodstream infections through hemodialysis catheters.¹¹

Beyond the bloodstream, S. hominis has caused peritonitis in peritoneal dialysis patients and, in rare cases, cellulitis around surgical implants.¹² Studies of bloodstream isolates have shown that these clinical strains can adhere to human cells, invade epithelial cells, and produce extracellular factors that damage tissue, suggesting a multifactorial approach to causing disease.¹³

Biofilm and Why It Matters for Device Infections

One reason S. hominis is particularly problematic on catheters and implants is its ability to form biofilms. A biofilm is essentially a slimy, structured community of bacteria that coats a surface and is much harder to kill than free-floating individual cells. Antibiotics that easily wipe out bacteria in a test tube often fail against the same species once it has organized itself into a biofilm on a catheter tip or a prosthetic surface. Research specifically targeting S. hominis biofilms has confirmed that these isolates commonly produce biofilm on medical-grade materials, and that standard lab testing methods may underestimate their resistance when grown in biofilm form.¹⁴

This biofilm-forming tendency helps explain why catheter removal is so often necessary to clear an S. hominis bloodstream infection. The bacteria embed themselves in the biofilm on the device and seed the bloodstream repeatedly. Antibiotics alone often cannot sterilize the device.

A Growing Problem With Antibiotic Resistance

Antibiotic resistance in S. hominis is widespread, particularly among strains isolated from hospitals. In one study of bloodstream isolates, about 81% carried the mecA gene, which confers resistance to methicillin and related antibiotics like oxacillin.¹⁵ A separate study of pediatric bloodstream infections found a similar rate: roughly 84% of S. hominis isolates were oxacillin-resistant and carried mecA.¹⁶

Methicillin resistance is just the start. Hospital strains of S. hominis frequently resist multiple drug classes. A multidrug-resistant isolate studied in Malaysia, for example, carried genes conferring resistance to tetracyclines via an efflux pump and reduced susceptibility to fluoroquinolones via yet another pump.¹⁷ Resistance to macrolide-lincosamide-streptogramin B (MLSB) antibiotics, a class that includes erythromycin and clindamycin, is also common among S. hominis clinical isolates.¹⁸

A worrying feature is that much of this resistance sits on mobile genetic elements — bits of DNA that can hop between bacteria. This means S. hominis does not just resist antibiotics for itself; it can potentially pass resistance genes to other staphylococcal species, including S. aureus. Isolates from companion animals in Thailand have also been found to harbor nontypeable resistance elements, reinforcing concerns that these genes circulate broadly.¹⁹

Vancomycin and linezolid remain reliable options for most S. hominis infections, but even here the margins are narrowing. The epidemiological cutoff value for norvancomycin (a vancomycin analog used in some countries) is 1 mg/L for S. hominis, which is lower than the cutoff for S. epidermidis or S. haemolyticus, suggesting S. hominis remains more sensitive to this drug class for now.²⁰

Contamination or True Infection

One of the trickiest clinical problems with S. hominis is figuring out whether a positive blood culture actually means infection or simply contamination. Because S. hominis lives abundantly on skin, it can easily get into a blood sample during the collection process. Clinicians drawing blood have to puncture the skin, and a few bacteria from the skin surface can hitch a ride into the collection bottle, producing a “positive” culture that does not reflect what is happening inside the patient’s body.

Distinguishing real from false results has practical consequences: a true bloodstream infection may require weeks of intravenous antibiotics and catheter removal, while a contaminated sample needs no treatment at all. One useful approach is checking how many blood culture bottles grow the organism. A pattern where all four bottles in a standard blood culture set turn positive strongly suggests a true S. hominis bloodstream infection rather than contamination.¹² Clinical context also matters: a positive culture in a febrile patient with a central line and no other obvious source of infection is far more concerning than a single positive bottle in a patient who feels fine.

Modern identification technology has made species-level identification much faster. Mass spectrometry-based platforms can correctly identify S. hominis, including at the subspecies level, with accuracy above 99%, replacing older methods that were slower and less precise.²¹ This speed helps clinicians make faster decisions about whether to treat and which antibiotics to use.

Treatment When Infection Is Confirmed

When S. hominis does cause a genuine infection, treatment depends on the site and the antibiotic susceptibility profile. For catheter-related bloodstream infections, the standard approach usually involves removing the infected catheter whenever possible, combined with appropriate antibiotics. Given the high rates of methicillin resistance, vancomycin is often the first-line choice for serious infections.

Linezolid provides an alternative, particularly when vancomycin is not tolerated or when an oral option is needed. In one case report, a peritoneal dialysis patient developed S. hominis peritonitis caused by a strain sensitive only to vancomycin and linezolid. The patient was successfully treated with oral linezolid without catheter removal, and adequate drug levels in the peritoneal fluid were confirmed during the 21-day course.²² Daptomycin lock therapy, where the antibiotic is instilled directly into the catheter lumen, has also been used for long-term catheter infections caused by S. hominis and other gram-positive organisms.²³

These are all hospital-level interventions. If you are a healthy person whose routine blood work incidentally grows S. hominis, the most likely explanation is contamination, and your doctor will probably recommend repeating the cultures rather than starting antibiotics.

S. Hominis in Skincare Research

In a curious twist, the same bacterium that causes trouble in hospitals is being explored as a potential beauty ingredient. The logic follows from its role as a beneficial commensal: if S. hominis helps maintain a healthy skin microbiome, deliberately applying it might improve skin condition. A small study of 11 healthy Japanese women tested this idea by applying S. hominis to one cheek for a month while using a placebo on the other. The treated side showed improvements in visible pore count, melanin levels, and wrinkle count compared to the placebo side.²⁴

This is still very early-stage research from a tiny sample, so nobody should run out and smear bacteria on their face based on it. But it illustrates how the relationship between humans and S. hominis is more nuanced than “good germ” versus “bad germ.” The same species occupies both roles depending on the context: protective partner on healthy skin, opportunistic invader in the immunocompromised, and maybe even a cosmetic tool if the science matures. Few bacteria wear quite so many hats.